Aldevron vs Kaneka Eurogentec: CDMO Comparison
How does Aldevron compare to Kaneka Eurogentec for mRNA/LNP manufacturing?
Side-by-side comparison of Aldevron and Kaneka Eurogentec on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- Kaneka Eurogentec holds 4 active EMA GMP certificates; Aldevron does not appear in EudraGMDP.
On a 13-modality CDMO landscape, both Aldevron and Kaneka Eurogentec qualify as mRNA/LNP manufacturers; Aldevron carries the higher composite Signal Score for mRNA/LNP programs in this comparison.
What to evaluate for mRNA/LNP programs
Both Aldevron and Kaneka Eurogentec qualify as mRNA/LNP CDMOs. When choosing between them for mRNA/LNP programs, weigh these four dimensions specifically — each carries through to the side-by-side scorecard above.
IVT mRNA synthesis
Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost.
LNP formulation
LNP encapsulation via microfluidics determines potency and tolerability. Confirm lipid sourcing, formulation freedom-to-operate, and particle-size control.
Plasmid / starting material
mRNA needs a DNA template. Check whether the CDMO supplies GMP plasmid in-house or coordinates a plasmid CDMO — it affects timelines.
Cold chain & stability
mRNA-LNP products are temperature-sensitive. Evaluate frozen storage, fill-finish, and the stability program.
Frequently asked: Aldevron vs Kaneka Eurogentec
How does Aldevron compare to Kaneka Eurogentec for mRNA/LNP manufacturing?
On CDMO Signal's composite Signal Score, Aldevron is 80/100 and Kaneka Eurogentec is 80/100; Aldevron has 1 FDA inspection on record vs 1 for Kaneka Eurogentec; European coverage is 0 active EMA+MHRA certificates for Aldevron vs 4 for Kaneka Eurogentec. Both are tracked in the CDMO Signal directory as mRNA/LNP CDMOs. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, Aldevron or Kaneka Eurogentec?
Both Aldevron and Kaneka Eurogentec maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. Aldevron has 1 FDA inspection on record; Kaneka Eurogentec has 1.
How do Aldevron and Kaneka Eurogentec compare on European GMP coverage?
Aldevron holds 0 active EMA GMP certificates and 0 MHRA / UK certificates. Kaneka Eurogentec holds 4 active EMA GMP certificates and 0 MHRA / UK certificates. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
Which is better for mRNA/LNP manufacturing — Aldevron or Kaneka Eurogentec?
Both Aldevron and Kaneka Eurogentec are tagged as mRNA/LNP CDMOs in our directory, so both are credible options for mRNA/LNP programs. The most important differentiator for mRNA/LNP selection is typically ivt mrna synthesis: Assess in-vitro transcription scale, capping strategy (co-transcriptional vs enzymatic), and template sourcing. These drive yield, purity, and cost. Review each CDMO's profile and inspection record before shortlisting.
What does the Signal Score gap mean in practice?
Aldevron carries a Signal Score of 80/100 and Kaneka Eurogentec carries 80/100 — essentially tied for Aldevron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →